Clinical bottom line
Allergic reactions to radiocontrast media (RCM) remain a significant concern in allergy and radiology practice due to their potential severity and diagnostic challenges. Recent evidence underscores the heterogeneity of these reactions, involving both immediate and delayed hypersensitivity mechanisms, and highlights evolving approaches for diagnosis and management. Premedication protocols, risk stratification, and emerging diagnostic tools such as basophil activation tests (BAT) offer promise but require further validation. Clinicians should maintain vigilance for RCM hypersensitivity, individualize preventive strategies, and collaborate closely with radiology and allergy specialists to optimize patient safety.
What the evidence shows
Radiocontrast media allergic reactions encompass immediate (within 1 hour) and delayed (hours to days) hypersensitivity responses, with clinical manifestations ranging from mild urticaria to life-threatening anaphylaxis (Brockow et al., 2009). Immediate reactions are often non-IgE-mediated but can involve allergic mechanisms, while delayed reactions are typically T-cell mediated (Brockow et al., 2009).
Hershkowitz et al. (2025) reported on a large hospital cohort, demonstrating that the incidence of clinically significant RCM allergy is relatively low but non-negligible, with most reactions being mild to moderate. Their data emphasize that careful patient history and risk assessment remain cornerstones of management.
Premedication with corticosteroids and antihistamines is widely used to reduce reaction risk, but Sodagari et al. (2024) found considerable variability in premedication practices among radiologists, reflecting uncertainty about optimal protocols. While premedication may reduce incidence of mild reactions, it does not eliminate severe hypersensitivity and is not universally effective.
Diagnostic advances include the basophil activation test (BAT), which shows promise in identifying immediate hypersensitivity to iodinated contrast media. Chirumbolo et al. (2013) demonstrated BAT’s potential utility in confirming allergic mechanisms, though its sensitivity and specificity require further study before routine clinical adoption.
Alternative contrast agents such as gadolinium-based or ferumoxytol have been explored for patients with RCM allergy. Nguyen et al. (2019) reported the off-label use of ferumoxytol as a safer MRI contrast in high-risk patients, but data remain limited and off-label use should be cautious.
Mohta et al. (2024) provide a concise overview of RCM allergic reactions, reinforcing the need for individualized risk stratification and highlighting that desensitization protocols are emerging but not yet standard practice.
Caveats and uncertainty
The pathophysiology of RCM reactions is complex and incompletely understood, with overlapping allergic and non-allergic mechanisms complicating diagnosis. The lack of standardized, validated diagnostic tests limits definitive identification of true allergy versus non-immunologic adverse reactions.
Premedication efficacy is supported mainly by observational data; randomized controlled trials are scarce, and no consensus exists on optimal regimens or patient selection criteria (Sodagari et al., 2024). Overreliance on premedication may provide false reassurance and delay recognition of breakthrough reactions.
BAT and other in vitro tests remain investigational, with variable performance across centers and contrast agents. Their role as adjuncts to clinical history and skin testing is promising but not yet established in guidelines.
Alternative contrast agents such as ferumoxytol carry their own risks and are not universally available or approved for routine imaging, limiting their applicability (Nguyen et al., 2019).
Finally, many studies derive from single-center cohorts or surveys, limiting generalizability. Large, multicenter prospective studies are needed to refine risk stratification and management algorithms.
How this may change practice
Clinicians should continue to prioritize detailed allergy histories focusing on prior RCM exposure and reaction characteristics. Collaboration with allergy specialists for skin testing or BAT may be considered in selected cases to clarify hypersensitivity status.
Premedication remains a pragmatic approach for patients with prior mild to moderate reactions, but clinicians should counsel patients on its limitations and maintain readiness to manage breakthrough reactions.
In patients with confirmed RCM allergy, alternative imaging modalities or contrast agents should be considered, balancing diagnostic needs and safety. Emerging diagnostic tests like BAT may become valuable adjuncts pending further validation.
Education of radiology teams on current evidence and consensus recommendations can reduce practice variability and improve patient outcomes. Future integration of standardized protocols for diagnosis and desensitization may enhance care for high-risk patients.